Abeona Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

The following table summarizes stock option-based compensation for the three months ended March 31, 2020 and 2019:

	For the three months ended March 31,
	2020		2019
Research and development	$	744,000	$	1,032,000
General and administrative		512,000		1,071,000
Stock option-based compensation expense included in operating expense		1,256,000		2,103,000

Total stock option-based compensation expense		1,256,000		2,103,000
Tax benefit		-		-
Stock option-based compensation expense, net of tax	$	1,256,000	$	2,103,000

We used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:

	For the three months ended March 31,
	2020			2019
Expected volatility		111	%		109	%
Expected term		6.25 years			5 years
Risk-free interest rate		0.43	%		2.46	%
Expected dividend yield		0	%		0	%

The following table summarizes the options granted for the periods indicated:

	For the three months ended March 31,
	2020		2019
Options granted		1,175,927		201,000
Weighted-average:
Exercise price	$	1.45	$	6.69
Grant date fair value	$	1.21	$	5.29

The following table summarizes restricted common stock compensation expense for the three months ended March 31, 2020 and 2019:

	For the three months ended March 31,
	2020		2019
Research and development	$	325,000	$	-
General and administrative		139,000		172,000
Restricted stock-based compensation expense included in operating expense		464,000		172,000

Total restricted stock-based compensation expense		464,000		172,000
Tax benefit		-		-
Restricted stock-based compensation expense, net of tax	$	464,000	$	172,000